RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Reata Pharmaceuticals Stock

Reata Pharmaceuticals ROE 2024

Reata Pharmaceuticals ROE

4.75

Ticker

RETA

ISIN

US75615P1030

WKN

A2ALQV

In 2024, Reata Pharmaceuticals's return on equity (ROE) was 4.75, a -396.93% increase from the -1.6 ROE in the previous year.

Reata Pharmaceuticals Aktienanalyse

What does Reata Pharmaceuticals do?

Reata Pharmaceuticals Inc is a biopharmaceutical company that was founded in Irving, Texas in 2002. The company develops and markets innovative therapeutics for severe and rare diseases, particularly rare genetic metabolic diseases, neurological diseases, and inflammatory diseases. Reata Pharmaceuticals has a unique business model based on the principle of "platform technology". This means that the company develops various therapeutic approaches based on a patented molecular platform. This platform allows Reata to quickly and efficiently develop new products for different disease areas. An important focus of Reata Pharmaceuticals' activities is the development of therapeutics for rare genetic metabolic diseases. The company has made remarkable progress in this area. In particular, the drug Omaveloxolone, which was developed for the treatment of Friedreich's ataxia, has attracted a lot of attention. This rare disease manifests as progressive spastic paralysis and can eventually lead to death. The drug has shown promising results in a Phase 2 study and is currently in Phase 3 study. Another important area for Reata Pharmaceuticals is inflammatory diseases. The company has developed a product called Bardoxolone Methyl, which is approved for the treatment of chronic kidney disease and pulmonary hypertension. These diseases have a significant impact on the quality of life and life expectancy of patients. Bardoxolone Methyl has shown in clinical studies that it can slow disease progression and significantly improve symptoms. In addition to these two pillars of activity, Reata Pharmaceuticals also has various product candidates for neurological diseases, cancer, and other diseases in the pipeline. The company aims to develop innovative solutions for unmet medical needs and help patients whose needs have not been adequately addressed. The history of Reata Pharmaceuticals is characterized by a successful path as a company with a unique business model. The company aims to play a leading role in the development and marketing of therapeutics for rare and serious diseases. To achieve this, the company has built a strong research and development team and works closely with the academic community. Reata Pharmaceuticals has managed to establish an international network of leading scientists, doctors, and patient organizations. This collaboration is crucial for the successful development and marketing of therapeutics for rare diseases. In summary, Reata Pharmaceuticals Inc is an innovative biopharmaceutical company that uses a unique platform technology for the development of therapeutics for rare and severe diseases. The company has made remarkable progress in the development of therapeutics for rare genetic metabolic diseases and inflammatory diseases and is working on additional products for neurological diseases, cancer, and other diseases. Reata Pharmaceuticals aims to play a leading role in the industry and help patients whose needs have not been adequately addressed. Reata Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Reata Pharmaceuticals's Return on Equity (ROE)

Reata Pharmaceuticals's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Reata Pharmaceuticals's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Reata Pharmaceuticals's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Reata Pharmaceuticals’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Reata Pharmaceuticals stock

What is the ROE (Return on Equity) of Reata Pharmaceuticals this year?

The ROE of Reata Pharmaceuticals this year is 4.75 undefined.

How has the Return on Equity (ROE) of Reata Pharmaceuticals developed compared to the previous year?

The ROE of Reata Pharmaceuticals has increased by -396.93% decreased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Reata Pharmaceuticals?

A high ROE indicates that Reata Pharmaceuticals generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Reata Pharmaceuticals?

A low ROE can indicate that Reata Pharmaceuticals is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Reata Pharmaceuticals affect the company?

A change in ROE (Return on Equity) of Reata Pharmaceuticals can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Reata Pharmaceuticals?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Reata Pharmaceuticals?

Some factors that can influence Reata Pharmaceuticals's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Reata Pharmaceuticals pay?

Over the past 12 months, Reata Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Reata Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Reata Pharmaceuticals?

The current dividend yield of Reata Pharmaceuticals is .

When does Reata Pharmaceuticals pay dividends?

Reata Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Reata Pharmaceuticals?

Reata Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Reata Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Reata Pharmaceuticals located?

Reata Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Reata Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Reata Pharmaceuticals from 11/16/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/16/2024.

When did Reata Pharmaceuticals pay the last dividend?

The last dividend was paid out on 11/16/2024.

What was the dividend of Reata Pharmaceuticals in the year 2023?

In the year 2023, Reata Pharmaceuticals distributed 0 USD as dividends.

In which currency does Reata Pharmaceuticals pay out the dividend?

The dividends of Reata Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Reata Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Reata Pharmaceuticals

Our stock analysis for Reata Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Reata Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.